Discover 1,584 paid clinical trials in Aurora, Colorado. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,584
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
for
Ganglioneuroblastoma, Nodular, Neuroblastoma
Location: Aurora CO, Salt Lake City UT, Wichita KS, Lubbock TX,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 0 - 30
Code: NCT06172296
Phase3, Recruiting
Project: Every Child for Younger Patients With Cancer
for
Adrenal Gland Pheochromocytoma, Carcinoma In Situ,
Location: Aurora CO, Denver CO, Albuquerque NM, Salt Lake City UT,
Sponsor: Children's Oncology Group
Sex: All
Age: 0 - 25
Code: NCT02402244
Recruiting
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
for
Metastatic Malignant Neoplasm in the Lung,
Location: Aurora CO, Denver CO, Albuquerque NM, Salt Lake City UT,
Sponsor: Children's Oncology Group
Sex: All
Age: 0 - 50
Code: NCT05235165
Phase3, Recruiting
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
for
Acute Myeloid Leukemia
Location: Aurora CO, Denver CO, Salt Lake City UT, Omaha NE,
Get alerts for new trials in your area by subscribing now
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
for
Neoplasms, Child, Adolescent
Location: Denver CO, Kansas City MO, Phoenix AZ, Dallas TX,
Sponsor: Eli Lilly and Company
Sex: All
Age: 1 - 39
Code: NCT05999994
Phase2, Recruiting
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
for
Hematopoietic and Lymphatic System Neoplasm,
Location: Aurora CO, Denver CO, Garden City KS, Albuquerque NM,
Sponsor: Children's Oncology Group
Sex: Female
Age: 0 - 39
Code: NCT06513962
Phase3, Recruiting
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia